

Reply to the Letter to the Editor from Egorin

In Response: Shortly after publication of our article in the November 1, 2007, issue of *Clinical Cancer Research*, we became aware that a conversion error led to incorrectly low carboplatin plasma ultrafiltrate AUC, impacting the scaling of the x axis in Fig. 2B and the carboplatin plasma ultrafiltrate results in Table 4. This results in median carboplatin plasma ultrafiltrate AUC of 4.77 mg/mL-min (and not as suggested 1.33 mg/mL-min). The conversion error, however, did not impact the correlation between carboplatin exposure and drug toxicity or clinical outcome. The corrected Fig. 2B is presented here.




Fig. 2. B, relative thrombocytopenia as a function of carboplatin plasma ultrafiltrate AUC (mg-min/mL; $R^2 = 0.26$, Pearson correlation coefficient 0.51, $P < 10^{-3}$).

Markus Joerger
Department of Oncology and Hematology,
Cantonal Hospital,
St. Gallen, Switzerland

Jan H.N. Schellens
Department of Medical Oncology,
The Netherlands Cancer Institute,
Amsterdam, the Netherlands

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Clinical Cancer Research

Reply to the Letter to the Editor from Egorin

Markus Joerger and Jan H.N. Schelleus

Clin Cancer Res 2008;14:2517.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/14/8/2517.2>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/14/8/2517.2>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.